| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A clinical trial of IL-15 and IL-21 combination therapy for COVID-19 is warranted
|
Wilz, Stephen W.
|
|
|
58 |
C |
p. 49-50
|
article
|
| 2 |
AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm
|
Gangemi, Sebastiano
|
|
|
58 |
C |
p. 111-113
|
article
|
| 3 |
Covid-19 in Brazil: A sad scenario
|
Marinho, Pedro Rafael D.
|
|
|
58 |
C |
p. 51-54
|
article
|
| 4 |
Cytokine storm with rapidly elevated interleukin-6 indicates sudden death in patients with critical COVID-19
|
Hu, Zhigang
|
|
|
58 |
C |
p. 30-31
|
article
|
| 5 |
Editorial Board
|
|
|
|
58 |
C |
p. ii
|
article
|
| 6 |
Glycogen synthase kinase-3: A putative target to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
|
Rana, Anil Kumar
|
|
|
58 |
C |
p. 92-101
|
article
|
| 7 |
Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity
|
Opdenakker, Ghislain
|
|
|
58 |
C |
p. 134-140
|
article
|
| 8 |
Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities?
|
Brandão, Simone Cristina Soares
|
|
|
58 |
C |
p. 102-110
|
article
|
| 9 |
Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy
|
Barros, Inês
|
|
|
58 |
C |
p. 114-133
|
article
|
| 10 |
Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19
|
Fouladseresht, Hamed
|
|
|
58 |
C |
p. 32-48
|
article
|
| 11 |
Response to: Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella
|
Prattichizzo, Francesco
|
|
|
58 |
C |
p. 141-143
|
article
|
| 12 |
SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders
|
Amruta, Narayanappa
|
|
|
58 |
C |
p. 1-15
|
article
|
| 13 |
SARS-CoV-2: Targeted managements and vaccine development
|
Bakhiet, Moiz
|
|
|
58 |
C |
p. 16-29
|
article
|
| 14 |
The cytokine storm in COVID-19: Further advances in our understanding the role of specific chemokines involved
|
Coperchini, Francesca
|
|
|
58 |
C |
p. 82-91
|
article
|
| 15 |
The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy
|
Li, Jing
|
|
|
58 |
C |
p. 75-81
|
article
|
| 16 |
Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors
|
Quarleri, Jorge
|
|
|
58 |
C |
p. 55-65
|
article
|
| 17 |
Type I IFN-dependent antibody response at the basis of sex dimorphism in the outcome of COVID-19
|
Gabriele, Lucia
|
|
|
58 |
C |
p. 66-74
|
article
|
Journal description